Nivolumab-Related Dry Mouth and Dry Eye: Cross-Sectional Study
dc.contributor.author | Yildirim, Ozgen Ahmet | |
dc.contributor.author | Poyraz, Kerem | |
dc.contributor.author | Erdur, Erkan | |
dc.contributor.author | Can, Canan | |
dc.contributor.author | Gundogan, Cihan | |
dc.contributor.author | Guzel, Yunus | |
dc.contributor.author | Etem, Hulya | |
dc.date.accessioned | 2024-04-24T16:24:36Z | |
dc.date.available | 2024-04-24T16:24:36Z | |
dc.date.issued | 2021 | |
dc.department | Dicle Üniversitesi | en_US |
dc.description.abstract | To evaluate ICIs related dry eye and dry mouth in nivolumab therapy, 24 patients receiving nivolumab (group 1), 30 patients in remission without treatment for 6 months (group 2), 30 healthy participants (group 3) were cross-sectionally examined. Schirmer's 1, 2, TSH blood tests, serological analysis, salivary flow scintigraphy and minor-salivary gland biopsy were performed. Schirmer's tests were performed with anesthetic (1) and without anesthetic (2). Schirmer's scores were lower in group 1 with more frequent reduced tear production (p < 0.001). TSH levels negatively correlated with Schirmer's scores. Functional insufficiency was detected by salivary flow scintigraphy in 7 out of 10 patients with Schirmer's test positivity. In Schirmer's positive patients, lymphocytic sialadenitis was confirmed in 4 patients (focus score > 1) and CD4 T lymphocyte precipitation was observed in 6 patients. Nivolumab therapy may be associated with ICIs related immune sicca. | en_US |
dc.identifier.doi | 10.1080/07357907.2021.1971241 | |
dc.identifier.endpage | 807 | en_US |
dc.identifier.issn | 0735-7907 | |
dc.identifier.issn | 1532-4192 | |
dc.identifier.issue | 10 | en_US |
dc.identifier.pmid | 34415812 | en_US |
dc.identifier.startpage | 797 | en_US |
dc.identifier.uri | https://doi.org/10.1080/07357907.2021.1971241 | |
dc.identifier.uri | https://hdl.handle.net/11468/16784 | |
dc.identifier.volume | 39 | en_US |
dc.identifier.wos | WOS:000698272500001 | |
dc.identifier.wosquality | Q4 | |
dc.indekslendigikaynak | Web of Science | |
dc.indekslendigikaynak | PubMed | |
dc.language.iso | en | en_US |
dc.publisher | Taylor & Francis Inc | en_US |
dc.relation.ispartof | Cancer Investigation | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Reduced Tear Production | en_US |
dc.subject | Nivolumab | en_US |
dc.subject | Schirmer's | en_US |
dc.title | Nivolumab-Related Dry Mouth and Dry Eye: Cross-Sectional Study | en_US |
dc.type | Article | en_US |